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Abstract
The molecular chaperone GRP78/BiP is a key regulator of protein folding in the endoplasmic reticulum, and it plays a pivotal
role in cancer cell survival and chemoresistance. Inhibition of its function has therefore been an important strategy for
inhibiting tumor cell growth in cancer therapy. Previous efforts to achieve this goal have used peptides that bind to GRP78/
BiP conjugated to pro-drugs or cell-death-inducing sequences. Here, we describe a peptide that induces prostate tumor cell
death without the need of any conjugating sequences. This peptide is a sequence derived from the cochaperone Bag-1. We
have shown that this sequence interacts with and inhibits the refolding activity of GRP78/BiP. Furthermore, we have
demonstrated that it modulates the unfolded protein response in ER stress resulting in PARP and caspase-4 cleavage.
Prostate cancer cells stably expressing this peptide showed reduced growth and increased apoptosis in in vivo xenograft
tumor models. Amino acid substitutions that destroyed binding of the Bag-1 peptide to GRP78/BiP or downregulation of
the expression of GRP78 compromised the inhibitory effect of this peptide. This sequence therefore represents a candidate
lead peptide for anti-tumor therapy.
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Introduction
The glucose regulated protein GRP78 (also known as BiP,
immunoglobuling heavy chain binding protein) is a member of the
heat shock protein family and plays an important role in
maintaining cellular homeostasis [1]. It is the key regulator of
the unfolded protein response (UPR), a pathway activated upon
accumulation of unfolded peptides during stressful conditions such
as heat shock, acidosis, nutrient starvation and hypoxia [2].
GRP78 regulates the UPR by binding the transmembrane
sensor proteins PERK (PKR-like endoplasmic reticulum-resident
kinase), ATF6 (activating transcription factor 6) and IRE1a
(inositol-requiring enzyme a) (reviewed in [3]) leading on the one
hand to an increased transcription of molecular chaperones like
GRP78 itself, GRP94 and protein-disulfide isomerase (PDI) [4,5]
and on the other hand to protein synthesis shutdown by
phosphorylation of the alpha subunit of the eukaryotic initiation
factor eIF2a [6]. As a consequence of these two effects, cells
overcome being overloaded with aberrant peptides and they
survive [7]. However, prolonged eIF2a phosphorylation activates
the transcription factor ATF4 [8,9] leading to increased levels of
the pro-apoptotic factor CHOP (C/EBP homologous protein)
[10,11]. Activation of ER-stress mediated apoptosis results in
cleavage of caspsase 4, an ER-stress specific caspase, and of PARP
(poly(ADP)-ribosome polymerase) [12,13].
GRP78 is overexpressed in several types of tumors such as
prostate [14], breast [15,16] and colon and its expression often
correlates with poor prognosis [17,18,19]. However GRP78
downregulation by siRNA increases apoptosis and sensitizes cells
to chemotherapeutic drugs [20,21]. In general transformed cells
upregulate GRP78 level [15] to survive the adverse conditions of
the tumor microenvironment [22,23,24]. Several therapeutic
agents have therefore been targeted against the UPR or against
GRP78/BiP to curb tumor cell growth [25,26] but truly selective
inhibitors are yet to be identified [15]. In a search for further
inhibitors of GRP78/BiP that would be of therapeutic relevance,
we have used information on the regulation of ER stress by the
cochaperone Bag-1 [27] to identify a sequence from Bag-1 that
binds to and inhibits the action of GRP78/BiP.
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Bag-1 is a family of four polypeptides (Bag-1L, -1M, -1 and -1S)
with multifunctional domains that interacts with and regulates the
activities of diverse cellular proteins [28]. These proteins possess
divergent N-terminal sequences but a common centrally located
ubiquitin-like domain that forms a link for Hsc/Hsp70 to the
proteasome [29] and a conserved C-terminal Hsp70 binding
domain (otherwise known as the BAG domain) that binds to
Hsp70/Hsc70 and functions as a nucleotide exchange factor
[30,31]. Bag-1 has also been shown to regulate endoplasmic
reticulum (ER) stress-induced apoptosis [27] and to bind
GADD34, a component of the ER stress [32] but details of its
action are not known.
In this communication we show that Bag-1 binds to GRP78/
BiP through a peptide overlapping its ubiquitin-like domain. We
further show that the GRP78/BiP binding peptide of Bag-1
inhibits the action of GRP78/BiP and interferes with the UPR
leading to the induction of apoptosis. We have narrowed down this
peptide and identified a core motif of seven amino acids that
appears essential for binding to GRP78/BiP and for the negative
regulation of prostate tumor cell growth. This core sequence could
be the starting point of future therapeutics directed towards the
inhibition of GRP78/BiP action and of the UPR.
Materials and Methods
Cell Culture
Human benign prostatic hyperplasia cell line BPH-1 was
cultured in Dulbeccos modified Eagles medium (DMEM)
supplemented with glutamine. PC3 and DU145 cells were also
cultured in DMEM but without glutamine 22Rv.1, LNCaP and
PNT-2 cells were cultured in RPMI 1640. All the above culture
media were supplemented with 10% fetal bovine serum. RWPE-1
cells were cultured in keratinocyte serum free medium. All the
culture media were kept at 37uC in an atmosphere of 5% CO2.
Antibodies
Goat monoclonal antibody GRP78 (N20), rabbit polyclonal
antibodies against Bag-1 (C-16), eIF2a and phospho-PERK were
purchased from Santa Cruz Biotechnology, Heidelberg, Germany.
Rabbit polyclonal anti-GRP78 (ab21685), anti-GCN2 (ab37674),
anti-PERK (ab65142), anti-phospho-IRE1a (ab124945) antibo-
dies, rabbit monoclonal anti-phopsho-GCN2 (ab75836) antibody
and mouse monoclonal anti-b actin (ab8226) antibody were
purchased from Abcam, Cambridge, UK. Mouse antibody against
HA-tag (HA.11 clone 16B12) was purchased from Covance,
Munich, Germany. Rat monoclonal antibody against HA (3F10)
was purchased from Roche, Mannheim, Germany. Antibodies
against IRE1a, phospho-eIF2a CHOP, PARP and ATF4 were
purchased from Cell Signaling Technology, Frankfurt am Main,
Germany. Anti-ATF6 antibody was purchased from Imgenex,
Hamburg, Germany. Caspase 4 antibody was purchased from
MBL, Munich, Germany.
Expression Vectors and Plasmids
The expression vector pcDNA3.1-HA-Bag-1 encoding Bag-1
has been previously described by [33]. The construct encoding
Bag-1D68mer (Bag-1 lacking amino acids 202–269) was created by
replacement of Sac II-Xba I fragment of the Bag-1 cDNA in
a pcDNA3-Bag-1 construct. The construct pcDNA3-HA Bag-1
peptide (Bag1-L 202–269), N-terminal (Bag-1L 202–241), C-
terminal (Bag-1L 241–269), 19-mer (Bag-1L 202–220), DUbi (Bag-
1L 220–269) and 19-mer mutant (Bag-1L 202–220) peptides were
created by PCR amplification with an HA sequence. As a control,
we introduced the HA sequence into pcDNA3 vector to generate
the empty expression vector pcDNA3.1-HA. pcDNA3.1 Bag-
1DC47 (Bag-1 lacking the last 47 amino acids) was cloned into the
Bam HI-Xho I sites of pcDNA3.1-HA vector after PCR
amplification using pcDNA3.1-HA Bag-1 as template. For GST-
pull-down experiments, pGEX4T.1-Bag-1 68mer sequence,
pGEX4T.1-N-terminal peptide, pGEX4T.1-C-terminal peptide,
pGEX4T.1 Bag-1D Ubi, pGEX4T.1-19mer and pGEX4T.1-
19mer mutants were created by fusing PCR amplification
products of the respective Bag-1L sequence in frame with GST
in the vector pGEX4T.1. GST plasmids encoding for GST-fused
GRP78, GRP78-ATPase (GRP78 1–408), GRP78-SBD (GRP78
409–651) and Bag-1 isoforms were generated by PCR and cloned
into pGEX4T.1 after BamHI-XhoI digestion. The plasmid
pCMV6-GRP78 [34] was purchased from OriGene Technologies
(Darmstadt, Germany).
Cell Transfection, siRNA Knock-down and Western
Blotting
Unless otherwise stated, stable transfection was carried out in
22Rv.1 or BPH-1 cells with 10 mg of plasmid DNA using FuGene
6TM (Roche Diagnostics Mannheim, Germany) Stably transfected
22Rv.1 cells were selected with 0.8 mg/ml while BPH-1 cell clones
were selected with 1.2 mg/ml G418. LNCaP, PC3, DU145, PNT-
2 and RWPE-1 cell clones were selected with 1 mg/ml G418.
Specific downregulation of GRP78 expression was achieved by
transfecting siRNA-duplexes (GRP78:59-GGAGCGCAUU-
GAUACUAGATT-39) twice in 72 h using HiPerfectTM (Qiagen
Hilden, Germany). siRNA against GFP (59-GGCUACGUCCAG-
GAGCGCACC-39) was used as a control. Western blot analysis
was performed as previously described [35].
Co-immunoprecipitation
22Rv.1 cells were used for interaction studies of endogenous
Bag-1 and GRP78/BiP, while for the in vivo interaction of the Bag-
1 peptide and GRP78/BiP, HEK-293 cells were transfected with
a plasmid encoding HA-tagged Bag-1 peptide. Twenty-four hours
prior to the experiment, the cells in both cases were washed with
phosphate buffered saline (PBS) and treated with 20 mM
Dithiobis(succinimidyl propionate) (DSP) in PBS for 30 min at
room temperature. The reaction was stopped with 20 mM Tris
and the cells were lysed in 50 mM Tris-HCl pH 7.4, 120 mM
NaCl, 1 mM EDTA, 0.4% NP40 and 1% protease inhibitor
cocktail. Immunoprecipitation of GRP78/BiP was carried out
overnight at 4uC with anti-GRP78 antibody coupled to sepharose
A beads (Abcam, ab21685). Binding of endogenous Bag-1 or of
HA-peptide was determined by Western blotting using a Bag-1 or
an HA specific antibody.
Protein Expression and Sample Preparation
A TEV protease-cleavable GB1-fused Bag-1 peptide was
expressed in the Escherichia coli strain BL21 (DE3) pLys S. Uniform
labeling with 15N for NMR spectroscopy was achieved by growing
the bacteria in minimal medium supplemented with 0.5 g/l
15NH4Cl. The GB1-His6-tagged protein was purified over a Ni-
NTA column (Qiagen, Hilden, Germany), subsequently digested
with recombinant TEV protease and passed over a second Ni-
NTA column to remove both the fusion tag and the His6-tagged
protease. Finally, the protein buffer was changed to 20 mM
potassium phosphate, 100 mM NaCl, pH 6.8. Protein concentra-
tion was estimated by comparing the intensity of a 1D NMR
spectrum with that of a reference substance (DSS, 2,2-dimethyl-2-
silapentane-5-sulfonic acid).
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The GST-HA-tagged N-terminal and C-terminal peptides were
produced using standard protocol. The GST moiety was cleaved
off by digestion with thrombin according to the manufacturers
protocol (Roche, Mannheim, Germany). The resulting crude
peptide preparation was further purified by reversed phase HPLC
(C18 column; 250610 mm, Grace) with a water/acetonitrile
linear gradient. The identity and purity of the collected fractions
were analysed by MALDI-TOF mass spectrometry (Bruker
Autoflex III). The pH was neutralized prior to lyophilization.
The peptide was dissolved in 20 mM KPO4, pH 6.8. Protein
concentration was calculated from the optical density at 275 nm
using the absorbance of the tyrosines in the HA-tag.
CD Spectroscopy
The CD spectra of the peptides were recorded on a Jasco J-810
spectropolarimeter (Jasco Co., Tokyo, Japan) at 20uC, using
a water-thermostated cell holder. The concentrations of the Bag-1,
N-terminal and C-terminal peptides were 17 mM, 12 mM, and
11 mM, respectively. The CD spectra are averages of three scans
at a scan rate of 10 nm min21, 4 s response time and 1 nm band
width, and they were smoothened by the adaptive smoothing
method that is part of the Jasco Spectra Analysis software. The
buffer contribution was subtracted.
NMR Experiments
Protein concentration for the NMR experiment was 0.5 mM.
For chemical shift calibration and to compare relative signal
intensities, 0.2 mM DSS (2,2 Dimethyl-2-silpentane-5-sulfonic
acid) was added. 15N-HSQC spectra were acquired at 23uC on
a Bruker Avance II 600 spectrometer (Bruker, Karlsruhe)
equipped with a broadband triple resonance probe head with 4
scans per increment and a total of 128 increments in the indirect
dimension. Data were processed with NMRPIPE [36] and
analyzed using NMR VIEW.
Fluorescence Polarization Assays
Fluorescence polarization assays were carried out using an
Infinite F-200 reader (Tecan) with excitation at 490 nm and
emission at 535 nm.
Tumor Xenograft Studies
All animal experiments were performed according to European
and German statutory regulations. For generation of xenograft
models 56106 LNCaP cells were resuspended in a solution of 50%
MatrigelH (BD Bioscience, Heidelberg, Germany) in PBS or
56106 22Rv.1 cells in 100 ml of PBS were subcutaneously injected
into both flanks of 6–8 week-old athymic nude mice. Tumor size
was measured with a caliper every week. Tumors derived from the
injection of stable clones overexpressing the Bag-1 peptide were
analyzed over a period of 9 weeks while tumors from cells
transfected with the empty expression vector or expressing the N-
terminal, the C-terminal and the DN-peptide were analyzed over 5
weeks. Tumor size was assessed measuring three perpendicular
diameters according to the formula: V= (1/6) [p] (d1d2d3), where
p is a mathematic constant and d1, d2 and d3 represent the three
spatial dimensions (width, depth and height). Mice were eutha-
nized by cervical dislocation and the tumors removed for further
analysis.
GST-pull-down Experiments
Expression of GST fusion proteins for GST-pull-down experi-
ments were performed essentially as described previously [37].
Immunohistochemistry
Tissues were fixed in 10% formalin for 16 h at room
temperature, stored in ethanol (50%), paraffin embedded, and
sectioned 5 mm thick with a Leica RM 2155 microtome. Apoptotic
cells were detected via terminal deoxynucleotidyl transferase-
mediated deoxyuridine-triphosphate-biotin nick end labeling
(TUNEL) assay using the DNA fragmentation ApopTagH
peroxidase in situ apoptosis detection kit (Millipore, Schwalbach,
Germany).
Cell Viability Assay
CellTiter-BlueH cell viability assay kit (Promega) was used for
the determination of cell viability. Briefly 22Rv.1 cells stably
overexpressing the Bag-1 peptide were seeded into two 96 well
plate (4500 cells/well) and the measurements were performed in
triplicate. One plate was analyzed at day 0 and the other plate, 2
days later. Three hours after seeding, 20 ml of dye were added to
each well containing 100 ml of culture medium and incubated for
4 h at 37uC. Fluorescence was measured by the plate-reading
fluorometer FluoStar Optima (2001, BMG Labtechnology,
software version 1.10–0) and presented as the ratio of the value
at the excitation wavelength (560 nm) over the emission
wavelenght (590 nm). Cell proliferation was determined from the
difference between the fluorescence intensity at the final time point
and the value obtained at the day of seeding of the cells (day 0).
In vivo Refolding Assay
In vivo refolding assay was performed essentially according to
the method described by [38]. HEK-293 in a 70%-confluent
10 cm dish were transfected with b-actin-fire fly luciferase
construct (2 mg), pcMV6-GRP78 (3 mg), Bag-1 or Bag-1 peptides
in pcDNA3.1-HA (6 mg) and Renilla luciferase construct (0.5 mg)
for equal transfection control. Two days after transfection the cells
were divided into two and incubated in heat shock buffer (MOPS
20 mM and cycloheximide 20 mg/ml) for 30 min at 37uC. One
half of the transfected cells was heat shocked for 30 min at 45uC
and allowed to recover at 37uC for 30 min. The other half was left
untreated and used as control. At the end of the experiments, the
cells were harvested, lysed and luciferase activity was measured.
The activity measured for the non-heat shocked cells was set as
100% of refolded luciferase and the activity measurements of the
heat shocked cells were expressed relative this value.
Statistical Analysis
Unless otherwise stated calculations of statistical significance in
this work was performed according to Student’s t test.
Results
Bag-1 Interacts with GRP78/BiP
As Bag-1 is reported to mediate ER-stress and to interact with
one of the components of the UPS [27,32], we investigated
whether it also binds to GRP78/BiP, a key component in the ER
stress pathway. We first determined whether Bag-1 interacts with
GRP78/BiP in a GST pull-down assay using lysate from 22Rv.1
prostate cancer cells. Western blot analysis using a GRP78/BiP
specific antibody showed that all the members of the Bag-1 family
of proteins interacted with GRP78/BiP (Figure 1A). In vivo
interaction was also demonstrated in a co-immunoprecipitation
assay in which Bag-1 was shown to bind to GRP78/BiP in 22Rv.1
cells (Figure 1B). Furthermore, we could show a perinuclear
localization of Bag-1 and GRP78/BiP in an immunofluorescence
assay using 22Rv.1 cells (Figure 1C) implying an ER localization of
Bag-1. This finding was confirmed in another immunofluores-
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cence experiment where we could show colocalization of Bag-1
with an ER tracker (Figure S1).
To determine the domain of GRP78/BiP involved in its binding
to Bag-1, we used GST-fusion constructs of the two main regions
of GRP78/BiP (the ATPase and substrate binding domain-SBD)
(Figure 1D) in pull-down experiments with HEK-293 cells
overexpressing Bag-1. Western blot analysis showed that Bag-1
interacted not only with the full length GRP78/BiP but also with
its ATPase and SBD (Figure 1E). As Bag-1 is reported to bind to
the ATPase binding domain of the molecular chaperone Hsp70/
Hsp70 [39] and GRP78/BiP belongs to this family of chaperones
[40], our finding that the SBD of GRP78/BiP is also bound by
Bag-1 is rather intriguing and identifies a novel interaction site of
Bag-1 in the molecular chaperone family. We therefore used the
SBD of GRP78/BiP in further characterization of the interaction
of GRP78/BiP with Bag-1.
GST-pull down analyses were carried out with the SBD of
GRP78/BiP and lysate of HEK293 cell expressing the wild type
Bag-1, Bag-1DC47, a C-terminal deletion mutant or Bag-
1D68mer, an internal deletion mutant. These studies identified
an internal sequence of 68 amino acids as a target of interaction of
Bag-1 with GRP78/BiP (Figures 2A and B). Deletion of this
sequence (Bag-1D68mer) abolished the interaction of Bag-1 with
GRP78/BiP (Figure 2B lane 11) while expression of the 68 amino
acid sequence alone showed that it is indeed required for binding
the SBD of GRP78/BiP (Figure 2B lane 12). This finding was
further confirmed in an in vivo co-immunoprecipitation experiment
where an HA-tagged Bag-1 peptide expressed in HEK 293 cells
interacted with endogenous GRP78/BiP protein (Figure 2C lane
3).
Several studies have shown that GRP78/BiP cooperates with
PDI in refolding denatured proteins in vitro [41,42]. To determine
whether GRP78/BiP also possesses the ability to fold denatured
proteins in vivo, we adopted a refolding assay used previously to
determine the chaperone activity of Hsp70 in vivo [43] In this
assay, HEK-293 cells were transfected with a plasmid encoding
a luciferase gene and an expression plasmid for GRP78/BiP. The
cells were briefly heat shocked and thereafter the luciferase activity
of the transfected cells expressing GRP78/BiP was compared with
that of the non-GRP78/BiP expressing cells. This study showed
that overexpression of GRP78/BiP significantly enhanced lucifer-
ase activity after the heat shock (Figure 2D) demonstrating the
ability of GRP78/BiP to refold denatured luciferase in vivo. If the
cells were additionally transfected with Bag-1 or the 68 amino acid
Bag-1 peptide that binds GRP78/BiP, the refolding activity of
GRP78/BiP was reduced to the control level (Figure 2D). This was
not the case when Bag-1D68mer that does not bind GRP78/BiP
was cotransfected. These studies demonstrate that the Bag-1
peptide interferes with the refolding activity of GRP78/BiP.
However the Bag-1 peptide did not have any effect on the ATPase
activity of GRP78/BiP although Bag-1 increased this enzymatic
activity (Figures S2A and S2B). This indicates that the Bag-1
peptide functions differently from the full length Bag-1. We
therefore embarked on the characterization of this peptide as
a ligand for GRP78/BiP for future therapeutic use.
Utilization of a Bag-1 Peptide to Induce Apoptosis and
Reduce Prostate Cancer Cell Growth
During ER stress, unfolded peptides accumulate in the ER and
GRP78/BiP plays a pivotal role to adjust protein folding capacity
Figure 1. Bag-1 proteins interact with the molecular chaperone GRP78/BiP. A. The Bag-1 family of proteins binds GRP78/BiP. GST pull-down
assay was performed incubating 5 mg each of GST-fused Bag-1 proteins with 400 mg of 22Rv.1 cell lysate. Western blotting with a specific antibodiy
against GRP78/BiP was used to detect the binding and an anti-GST antibody was used to determine the amount of bacterially purified protein
employed in the assay. B. Bag-1 and GRP78 interact in vivo. GRP78 was immunoprecipitated with an anti-GRP78/BiP antibody or IgG as control in
22Rv.1 cells. Western blotting with an anti-Bag-1 and anti-GRP78 antibody was performed to determine GRP78-Bag-1 interaction. C. Bag-1 and
GRP78/BiP show a perinuclear colocalization. Confocal microscopic analyses were carried out in 22Rv.1 cells that have been paraformaldehyde-fixed
and stained with a Bag-1 antibody to detect Bag-1 (green channel) and a GRP78/BiP specific antibody to detect GRP78/BiP (red channel). The orange
staining in the merge of the two channels indicates the degree of co-localization of the two proteins. All images (40X) were acquired with a Leica TCS
SPE confocal microscope (Leica Microsystems; Scale bars indicate 25 mm). D. Diagrammatic representation of the domains of GRP78. E. Bag-1 binds to
multiple sites on GRP78. GST-pull down assay performed incubating 500 mg lysate of HEK-293 cells transfected with an HA-tagged Bag-1 and 10 mg
GST-fused GRP78 full length and its ATPase and substrate binding domain (SBD). Western blot analysis was carried out using an HA antibody to
detect the Bag-1-tagged protein. Shown is a Coomassie blue staining of the bacterially purified GST proteins to demonstrate equal loading of the GST
proteins.
doi:10.1371/journal.pone.0045690.g001
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by activating three signaling pathways (PERK, IRE1a, and ATF6)
[44,45]. PERK is autophosphorylated leading to the phosphory-
lation of the alpha subunit of eIF2 and protein synthesis shut-
down. Phosphorylated eIF2a selectively enhances translation of
the transcription factor ATF4 that increases UPR target gene
expression such as GRP78/BiP [44,45] and IRE1a is also
autophosphorylated leading to the activation of chaperone
synthesis via Xbp1 activation. ATF6 is proteolytically cleaved to
take part in the upregulation of expression of UPR target genes
[44,45]. However apoptosis is induced if homoeostasis cannot be
established [46]. We therefore determined whether binding of the
Bag-1 peptide to GRP78/BiP, the key component of ER stress,
affects the signaling pathways of the UPR.
We stably transfected 22Rv.1 prostate cancer cells with
a construct coding for an HA-tagged Bag-1 peptide or an empty
vector as control and treated the cells with thapsigargin that
induces stress by calcium depletion from the ER [47]. In the
22Rv.1 vector control transfected cells, all three arms of the UPR
were activated following treatment with thapsigargin (i.e. increased
phosphorylation of PERK, increased eIF2a phosphorylation,
enhanced expression of ATF4, increased IRE1a phosphorylation,
increased cleavage of ATF6 and increased expression of GRP78/
BiP (Figure 3A lanes 1–3). The increase cleavage of ATF6 was not
accompanied by a concomitant downregulation of uncleaved
ATF6 since thapsigargin enhanced the expression of this gene
(Figure S3A). This effect was not only observed in 22Rv.1 cells but
also seen in LNCaP prostate cancer cells at the protein level
(Figure S3B). The overexpression of the Bag-1 peptide affected all
three arms of this pathway. For example, there was reduced ER
stress-induced phosphorylation of PERK and IRE1 (Figure 3A
Figure 2. Identification of Bag-1 peptide interfering with the action of GRP78/BiP. A. Diagrammatic representation of Bag-1 and its
deletion mutants used for the identification of sequences required for binding the SBD of GRP78/BiP. Depicted in blue and red are the ubiquitin-like
domain and the BAG domain respectively. B. Identification of the Bag-1 peptide binding to GRP78/BiP. GST-pull down assay performed incubating
500 mg lysates from HEK-293 cells transfected with the indicated Bag-1 constructs and 10 mg of GST-GRP78(SBD) or GST as control. Western blot
analysis with an HA antibody to detected the Bag-1 mutants is shown. Coomassie blue staining was performed to demonstrate equal loading of the
GST fusion proteins. C. The Bag-1 68 amino acid peptide binds in vivo to GRP78. HEK 293 cells were co-transfected with pcDNA-HA-tagged Bag-1
peptide. The transfected cells were treated with 2 mM Dithiobis(succinimidylpropionate) to cross-link the proteins and the cell lysates were
immunoprecipitated with an anti-HA antibody or IgG as control, followed by Western blotting with an anti-GRP78/BiP antibody. D. The Bag-1 68
amino acid peptide inhibits GRP78/BiP refolding activity. In vivo luciferase refolding assay was performed in HEK-293 cells transfected at 70%
confluency with 2 mg b-actin-fire fly luciferase construct, 3 mg pcDNA3 empty vector as control or pCMV6-GRP78/Bip, 6 mg of the indicated
pcDNA3.1-Bag-1 or mutant constructs and 0.5 mg Renilla luciferase construct to determine the transfection efficiency. The transfected cells were
divided into two. One half was left untreated and the other half was heat shocked at 45uC for 30 min. Thereafter luciferase activity was measured.
Results are expressed as percentage of refolding activity relative to non-heat-shocked cells and presented as bar charts of the average of three
independent experiments 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0045690.g002
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lanes 4–6). There was also a significant reduction of cleaved ATF6
(Figure 3A lanes 4–6; Figures S3A and S3B) and an inhibition of
the thapsigargin-induced expression of GRP78/BiP (Figure 3A
lanes 4–6). Intriguingly an increase in eIF2a phosphorylation was
observed leading to activation of the downstream target ATF4
(Figure 3A lanes 4–6). As PERK is downregulated following
overexpression of the Bag-1 peptide, it cannot be the kinase
responsible for the increased phosphorylation of eIF2a in the
peptide expressing cells. It is likely that another kinase is
responsible for the increase phosphorylation of eIF2a Indeed we
could show that the upstream kinase, general control nonder-
epressible 2 (GCN2) is upregulated in the peptide expressing cells
(Figure S4). The enhanced phosphorylation of eIF2a phosphor-
ylation and activation of ATF4 in the peptide expressing cells are
correlated with an increased expression of the pro-apoptotic factor
CHOP indicating that the Bag-1 peptide induces apoptosis.
Further evidence that the peptide is involved in the induction of
apoptosis is shown in experiment in which we treated 22Rv.1 cells
with thapsigargin for 24 h and compared the CHOP expression in
control cells with cells expressing the Bag-1 peptide. Twenty-four
hours treatment resulted in induced CHOP expression accompa-
nied by an increase in PARP cleavage even in the control cells.
However the level of CHOP expression and PARP cleavage was
further enhanced in the cells expressing the Bag-1 peptide
indicating that the peptide sensitizes the cells to the apoptosis
inducing effect of thapsigargin. Following siRNA knockdown of
CHOP, PARP cleavage was reduced in both cells line indicating
that this protein is responsible for the apoptosis inducing effect
measured by PARP cleavage (Figure S5).
To determine if stress-induced apoptosis is indeed increased in
the presence of the Bag-1 peptide, the 22Rv.1 cells expressing this
peptide were treated with thapsigargin or glucose starved to
induced ER stress [45] and the expression of apoptotic markers
(caspase 4 and PARP) were analyzed. In the absence of the ER
stressors, both caspase 4 and PARP cleavage was increased in the
22Rv.1 cells overexpressing the Bag-1 peptide compared to the
vector control cell line (Figure 3B compare lane 4 with 1).
However in the presence of ER stress, a tremendous increase in
caspase 4 expression and PARP cleavage was observed in the Bag-
1 peptide expressing cells compared to the control (Figure 3B
compare lanes 5–6 with 2–3). These results confirm that the
expression of the Bag-1 peptide induces apoptosis as well as
sensitizing the prostate tumor cells to stress-induced apoptosis.
Further evidence of increased ER apoptosis by the Bag-1 peptide
is the enhanced expression of JNK and caspase 7 cleavage in the
22Rv.1 cells expressing the peptide compared to control vector
transfected cells in the presence of thapsigargin (Figure S6).
To find out whether the effect of the Bag-1 peptide is correlated
with the cellular levels of GRP78/BiP, the level of PARP cleavage
was compared in vector and Bag-1 peptide expressing 22Rv.1 cells
following the knock-down of GRP78/BiP by siRNA interference
technique. Consistent with the finding in Figure 3B, the expression
Figure 3. The Bag-1 peptide modulates the UPR and sensitizes 22Rv.1 cells to ER-stress. A. UPR modulation upon Bag-1 peptide
overexpression. Pooled clones of 22Rv.1 cells transfected with pcDNA3.1-HA-Bag-1 68 amino acid peptide or an empty expression vector were
treated with 300 nM thapsigargin (TG) for the indicated time points. Cells were lysed and subjected to Western blot analysis using the indicated
antibodies or phospho-specific antibodies. B. The Bag-1 peptide sensitizes 22Rv.1 cells to ER-stress induced apoptosis. Pooled clones of 22Rv.1
transfected with the Bag-1 peptide or the empty expression vector were treated with thapsigargin (TG) or glucose-starved (GS) for 24 h. The cells
were lysed and subjected to Western blot analysis using anti-PARP and caspase 4 specific antibodies. Anti-HA antibody was used to detect the HA-
Bag-1 peptide. Anti-b-actin antibody was used to demonstrate equal loading of the protein samples. C. GRP78 downregulation increases PARP
cleavage. Pooled clones of 22Rv.1 expressing HA-tagged Bag-1 peptide or an empty expression vector were transfected with GRP78/BiP siRNA or
control GFP siRNA. The cells were lysed and Western blot was carried out with anti-PARP, anti-GRP78 and anti-HA antibodies. b-actin antibody was
used to determine the level of protein loaded on the gel.
doi:10.1371/journal.pone.0045690.g003
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Figure 4. The Bag-1 peptide inhibits prostate cancer cell growth in vivo. A. Stable clones of 22Rv.1 cells show reduced cell viability in vitro.
Stable clones were seeded in a 96-well plate and the cell number in each well was estimated by measuring the ratio between the wavelength of
excitation and emission 560/590 nm using the CellTiter-BlueTM proliferation assay. The bar charts represent the mean of at least four independent
experiments 6SD (*p,0.05). B. Determination of the level of the Bag-1 expressed in the 22Rv.1 clones. Cellular extracts of 22v.1 stable clones were
subjected to Western blot analysis. An anti-HA antibody was used to detect the peptide and an anti-b-actin antibody for equal loading control. C-D.
The Bag-1 peptide reduces 22Rv.1 prostate tumor cell growth in vivo. Six-week old athymic nude mice were injected subcutaneously in both flanks
with 56106 cells of each stable clone. Tumor size was measured once per week using a caliper and expressed as tumor volume in mm3. Shown are (C)
the tumor volumes of clones transfected with empty expression vector and (D) clones expressing the Bag-1 peptide. Each point represents the mean
volume and standard deviation of at least 5 to 10 tumors. E. Xenografts of stable clones expressing the Bag-1 peptide show increased apoptosis. Five-
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of the Bag-1 peptide led to an increase in the PARP cleavage even
in the absence of ER stress (Figure 3C compare lanes 1 and 2).
However following the knock-down of GRP78/BiP, PARP
cleavage was enhanced in the control 22Rv.1 cells (Figure 3C
compare lane 3 with lane 1) but no difference in the cleavage
pattern was further observed in the cells expressing the Bag-1
peptide (Figure 3C compare lanes 3 and 4).
Bag-1 Specific Sequence Inhibits Prostate Tumor Cell
Growth
To better analyze the effect of the Bag-1 peptide on prostate cell
growth, we determined the proliferation of single 22Rv.1 cell
clones expressing either the Bag-1 peptide or an empty expression
vector using CellTiter-BlueTM proliferation assay. The peptide
clones (P25, P29 and P42), even in the absence of ER stress,
showed a significantly reduced proliferation compared to the
vector controls (V18, V19 and V33) (Figures 4A and B). When
these stably transfected cells were injected into athymic nude mice,
cells containing the empty expression vector developed tumors
with an average allowable volume of 1.2 cm3 in 4–8 weeks
(Figure 4C). In contrast, tumors generated by cells expressing the
peptide (P42, P25 and P29) only reached 0.4 cm3 in 9 weeks
(Figure 4D). This difference in tumor volume was also reflected in
the weight of the tumors determined at the end of the experiment
(Table 1). Note that in some cases (e.g. clone 25), the mice were
euthanized earlier than 9 weeks because the tumors were necrotic
(Table 1). Similar results on the inhibition of tumor cell growth in
athymic mice were obtained when the peptide was stably
expressed in the prostate tumor cell line LNCaP (Table 1).
Immunohistological studies were carried out on the tumors
generated by the 22Rv.1 cell clones using a TUNEL assay.
Consistent with the growth profile, tumors derived from the
control clones (V18, V19 and V33) showed very few TUNEL
positive cells. In contrast, tumors derived from the peptide-
expressing clones (P25, P29 and P42) showed strong signals
indicative of massive apoptosis particularly in the cells expressing
high levels of the Bag-1 peptide (Figure 4E) confirming a pro-
apoptotic action of the Bag-1 peptide even in an in vivo situation.
Structural Studies of the Bag-1 Peptide
The Bag-1 peptide we have shown to inhibit tumor cell growth
consists N-terminally of twenty amino acids that form an extended
loop and a b-sheet of the ubiquitin-like domain (1WXV.pdb),
followed by helix 1 of the BAG domain (1I6Z.pdb) (Figure 5A).
We used homology-based structure prediction methods, as de-
tailed in Text S1, to identify key structural features of this
sequence. The resulting model, which represents an idealized
average structure is shown in Figure 5B.
Structure analysis by circular dichroism (CD) showed that the
Bag-1 peptide adopts some residual a-helical structure in about
25% of its sequence (,17 residues), in agreement with the
structure prediction (Figure 5C black line). To identify the degree
of structural disorder, i.e. the degree of fluctuation around the
average structure, we analyzed 15N-HSQC spectra, which showed
only little dispersion (Figure 5D). The majority of the amide
protons resonated within a narrow range between 7.8 and
8.3 ppm (Figure 5D). No upfield-shifted signals indicative of
defined three-dimensional interactions were observed in the 1D
spectrum. This suggests that the partial helicity in the CD
spectrum does not originate from a well-defined three-dimensional
structure, but rather represents a tendency of this segment to
fluctuate around a mean helical structure. This interpretation is
consistent with the CD estimate of 17 a-helical-residues which is
only half of the 33 residues predicted by the model (Figure 5B). We
further dissected the peptide into two smaller fragments, a N-
terminal 40 residues (N-terminal) and a 28 C-terminal fragment
(C-terminal) (Figure 5A). The CD spectra of both fragments fused
to an HA-tag for solubility, revealed that in isolation both parts are
entirely unstructured as clearly seen from the pronounced
minimum at 198 nm and the absence of any positive ellipticity
below 200 nm (Figure 5C blue and green lines).
In GST-pull down assay with lysates from the 22Rv.1 cells, we
could show that although the peptides are unstructured, the N-
terminal but not the C-terminal peptide bound to GRP78/BiP
(Figure 5E compare lanes 2 and 5 with lane 3). This interaction is
however different from that of the full-length Bag-1 peptide. While
Bag-1 or the full length 68 amino acid peptide interacted with both
the SBD and ATPase binding domains of GRP78 (Figure 1E and
results not shown), the N-terminal peptide interacted preferentially
with the SBD (Figure S7). Deletion of the 19 amino acid ubiquitin-
like domain portion of the Bag-1 peptide (Figure 5A) abrogated
the binding to GRP78 (DUbi peptide, Figure 5E lane 4).
The binding activities of the truncated peptides correlated well
with their inhibitory action in cell growth assays. Only the full-
length Bag-1 peptide and the N-terminal peptide inhibited growth
of the 22Rv.1 cells in clonogenic assay while the C-terminal and
the DUbi peptide were ineffective (Figure 5F). The growth
inhibitory action of the peptides was also confirmed in xenograft
micron sections of formalin-fixed, paraffin-embedded tumor tissues were subjected to immunohistochemistry. Nuclei are stained blue-purple with
hematoxylin while apoptotic cells detected with the TUNEL assay are stained brown. Representative sections of xenografts obtained from each
22Rv.1 stable clone were acquired with an Axioscop microscope (Zeiss). V: stands for empty vector expressing clone and P: peptide expressing clone.
doi:10.1371/journal.pone.0045690.g004
Table 1. Effect of the Bag-1 peptide on tumor weights in
22Rv.1 and LNCaP xenograft tumor mouse models.
22Rv.1 cells
Clone No.
Tumor weight
(g)
Termination time
(weeks)
Vector clones V33 1.2460.61 4
V19 1.3660.54 4–5
V18 1.7360.48 7–8
Peptide clones P25 0.3160.14 7–9
P42 0.3860.20 9
P29 0.4260.17 9
LNCaP cells
Clone No. Tumor weight
(g)
Termination time
(weeks)
Vector clones V82 0.6560.29 8
V69 0.2260.03 6
Peptide clones P35 0.0560.01 6
P12 0.0460.03 8
Tumor weights and time of euthanasia of mice are recorded. The values
represent the mean weights and standard deviation calculated from 4–10
tumors and the time of euthanasia.
doi:10.1371/journal.pone.0045690.t001
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Figure 5. An N-terminal unfolded fragment of the Bag-1 peptide is sufficient to reduce tumor cell growth. A. Schematic diagram of the
Bag-1 peptide and its deletion mutants. The ubiquitin-like domain is represented in blue and the BAG domain in red. The numbers refer to the amino
acid positions of the different domains. The amino acid residues are numbered following the numbering for Bag-1L. B. Prediction of the secondary
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models using single clones of 22Rv.1 cell stably expressing the N-
terminal peptide. This effect was not seen with clones expressing
the C-terminal or DUbi peptides (Figures 5G-I). These results
together show that the sequence that extends into the ubiquitin-
like domain of Bag-1 is important for binding to GRP78/BiP and
for the inhibition of prostate tumor cell growth.
Further Truncation of the Bag-1 Peptide
Further N- and C-terminal truncations of the 19 amino acid
peptide (19mer) (Figure 6A) led to the identification of a seven
amino acid core peptide 214RVMLIGK220 as important for the
binding to GRP78/BiP (Figure 6B). This 7 amino acid core
sequence labeled with FITC bound the SBD of GRP78/BiP with
a KD of 5.760.8 mM as determined in a fluorescence polarization
experiment (Figure 6C). Competition experiments with an un-
labeled core sequence produced an IC50 of 2.660.5 mM while
a sequence with an exchange of the ‘‘VML’’ in the 7 amino acid
sequence with alanine residues (214RAAAIGK220) was unable to
compete for binding (IC50 of .100 mM) (Figure 6D). This
mutated core when introduced into the 202–220 amino acid
peptide (19-mer mutant) significantly reduced the ability of the 19
amino acid sequence to inhibit 22Rv.1 cell growth in the
clonogenic assay compared to the unmutated 19 mer (202–220)
or the N-terminal peptide (202–241) (Figure 6E). The 19-mer
peptide but not the 19-mer mutant peptide also inhibited the
ability of GRP78/BiP to refold denatured protein in the in vivo
luciferase refolding assay (Figure 6F).
To determine the selectivity of the Bag-1 peptide toward
inhibition of prostate cancer cell growth, we overexpressed the 19-
mer in a series of benign prostate cells and prostate cancer cell
lines and performed clonogenic assays with these cells. We could
show that the peptide inhibited growth of the prostate tumor cell
lines (LNCaP, DU145 and PC3) that express substantial levels of
GRP78 (Figures 6G and 6H). In contrast, the benign prostate cell
lines BPH-1, PNT-2 and RWPE-1 that marginally express this
molecular chaperone were not growth inhibited by the peptide
(Figures 6G and 6H).
These results together with our previous results in Figure 3C
show that the cell growth inhibitory action of the Bag-1 peptide is
correlated with the cellular levels of GRP78/BiP.
Discussion
GRP78/BiP is expressed in many human cancers where it
mediates tumor growth by enhancing proliferation, protecting
against apoptosis and promoting tumor angiogenesis. [48].
GRP78/BiP also favors cell survival and contributes to tumor
progression and drug resistance during ER stress that arises in the
tumor microenvironment as a result of hypoxia and nutrient
deprivation [15,49]. The maintenance of cellular homeostasis by
GRP78/BiP occurs in different tumors including prostate cancer
[50,51,52] and an increased expression of GRP78 has been
associated with castration resistance and androgen deprivation in
prostate cancer [50]. As a result, several attempts have been made
to target GRP78/BiP to trigger apoptosis in prostate cancers and
other forms of cancers. For example, a peptidic ligand of GRP78/
BiP fused to a programmed cell death-inducing sequence was
shown to suppress tumor growth in xenograft and isogenic models
of prostate and breast cancer [53]. Furthermore a peptidic ligand
of GRP78/BiP conjugated to taxol has been shown to exhibit
selective cytotoxicity against highly metastatic melanoma cells
[54]. In addition to peptide-drug conjugates, a number of peptides
and antibodies binding to the ATPase and substrate binding
domains of GRP78/BiP have been reported [55,56,57]. Some of
these affect the growth promoting and angiogenic action of
GRP78/BiP positively or negatively but their modes of action
have not been extensively investigated.
In the present study we made use of the ability of the co-
chaperone Bag-1 to bind GRP78/BiP to inhibit its refolding
activity to derive a Bag-1-based peptide for suppressing the growth
promoting action of GRP78/BiP. Our peptide interacts with the
C-terminal substrate binding domain of GRP78/BiP, a region
bound by an antibody that exerts pro-apoptotic function [58]
identifying the C-terminal region as a target for the elicitation of
apoptosis by GRP78/BiP.
The Bag-1 peptide we identified inhibited the refolding action of
GRP78/BiP and all three arms of the UPR since IRE1a and
PERK phosphorylation were inhibited as well as ATF6 cleavage.
However it activated the phosphorylation eIF2a, a downstream
effector of PERK indicating that this peptide also affects the action
of other regulators of eIF2a phosphorylation such as GCN2
[45,59]. Indeed we could show enhanced phosphorylation of
GCN2 in cells expressing the Bag-1 peptide (Figure S4).
Alternatively the Bag-1 peptide may increased phosphorylation
of eIF2a through inhibition of the action of GADD34, a cellular
stress response protein that binds protein phosphatase 1 (PP1) that
dephosphorylates eIF2a. Indeed we have observed that the Bag-1
peptide interact with GADD45 (results not shown) in agreement
with the reports that Bag-1 binds GADD34 and inhibits the
activity of PP1 [32]. Thus the Bag-1 peptide we have identified
targets other proteins in addition to GRP78/BiP to induce
apoptosis. The enhanced phosphorylation of eIF2a we see in the
presence of the Bag-1 peptide is correlated with enhanced
expression of the downstream targets ATF4 and CHOP [60,61].
As a consequence, the cells are more sensitive to stressors such as
thapsigargin or glucose starvation, as shown by the increase in
casepase 4 activity and PARP cleavage. We could also show that
structure of the Bag-1 peptide, showing an N-terminal b-hairpin from the ubiquitin-like domain (blue) and a C-terminal a-helix from the BAG domain
(red). C. Normalized circular dichroism spectra of the Bag-1 peptides. 30 mM of the Bag-1 peptide were measured in 20 mM KHPO4 buffer, pH 6.8
(black line). Its a-helical content was estimated to be approximately 25% by deconvolution of the spectra (red line). 12 mM of the N-term peptide
(green line) and 11 mM of C-term (blue line) were measured under the same conditions. D. 1H15N-HSQC NMR spectrum of 15N-labeled Bag-1 peptide
(202–269) in 20 mm KHPO4 buffer, pH 6.8, at 23uC. The narrow spectral dispersion indicates that the peptide does not exhibit a folded globular
structure. The Hd and He side chain signals of asparagine and glutamine are connected by thin lines. E. The N-terminal region of the Bag-1 peptide is
important for GRP78 binding. 400 mg of 22Rv.1 cell lysate were incubated with glutathione-agarose beads carrying 15 mg GST-N-term peptide (lane
2), GST-C-term peptide (lane 3), GST-DUbi peptide (lane 4), GST-Bag-1(202–269) peptide (lane 5) and GST (lane 6). The beads were washed and the
bound proteins were separated by 10% SDS-PAGE and subjected to Western blotting using antibodies directed against GRP78 or GST. The input lane
shows 1/10 aliquot of cell lysate used for the study. F. Clonogenic assay of the Bag-1 peptides expressed in 22Rv.1 cells. Cells transfected with the
indicated constructs were selected in medium containing neomycin and the colonies formed were quantified. Shown are the mean value6SEM of at
least three independent experiments using three different plasmid preparations (*p,0.05). G-I. The N-terminal peptide reduces tumor growth in vivo.
Six-week old athymic nude mice were injected subcutaneously on both flanks with 56106 cells of each stable clone. Tumor size was measured once
per week using a caliper and expressed as tumor volume in mm3. Shown are the tumor volumes of clones transfected with the N-terminal peptide
(G), the C-terminal peptide (H) and the DUbi peptide (I). Each point represents the mean volume and standard deviation of at least 5 to 10 tumors.
doi:10.1371/journal.pone.0045690.g005
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Figure 6. Selectivity of action of the Bag-1 peptide. A Amino acid sequence of the 19mer peptide and its deletion mutants. B GST pull-down
assay performed incubating 400 mg of 22Rv.1 cell lysate and 25 mg of GST-fused deletion mutants of the 19mer peptide. After the pull-down
experiment, Western blots were carried out with anti-GRP78/BiP and GST antibodies. C. Fluorescence polarization (FP) assays with a 10 nM FITC-
labeled 7-mer Bag-1 peptide and dilutions of the GST-fused substrate binding domain of GRP78 in 60 ml of Tris-GSH buffer (50 mM Tris, 10 mM
reduced glutathione and 0.1% BSA, pH 8.0). Triplicate samples were measured after 5 h of incubation at room temperature with an Infinite F-200
reader (Tecan) with excitation at 490 nm and emission at 535 nm. Binding constants were determined from three independent experiments using
non-linear regression in Sigma Plot 10.0. D. Competition assays with a complex of 10 nM of FITC-labeled Bag-1 7-mer peptide and 0.75 mg/ml GST-
fused GRP78 substrate binding domain was measured against a dilution series from 100 mM to 0.1 nM of wild-type Bag-1 7-mer peptide (filled line) or
triple mutant peptide (dotted line) in 40 ml of Tris-GSH buffer. FITC-peptide and the FITC-peptide-protein complex were used as controls.
Fluorescence polarization was determined as described above and IC50 values were determined in Sigma Plot. E. Clonogenic assay in 22Rv.1 cells with
pcDNA3 based vectors coding for the N-terminal Bag-1 peptide (positive control), the 19mer and the 19mer mutant fragments as well as the empty
expression vector (negative control). Cells were transfected with the indicated constructs and selected in medium containing neomycin. The colonies
were stained and quantified. Shown as bar chats are the mean 6 SEM of at least three independent experiments with three different plasmid
preparations. (*p,0.05). F. In vivo luciferase refolding assay was performed in HEK-293 cells transfected at 70% confluency with 2 mg b-actin-fire fly
luciferase construct, 3 mg pcDNA3 empty vector as control or pCMV6-GRP78, 6 mg pcDNA3.1-HA-19-mer or 19-mer mutant peptide and 0.5 mg Renilla
luciferase construct to determine the transfection efficiency. Shown as bar charts is the mean of at least three different experiments6 SEM (*p,0.05).
G. Clonogenic assay with the indicated malignant (LNCaP, DU145, PC3) and benign (BPH1, PNT2, RWPE1) prostate cell lines transfected with the
vector control (black bars) and a vector expressing the 19-mer peptide (white bars). Shown are the mean6 SD of at least three different experiments
performed with three different plasmid preparations (*p,0.05). H. Western blot analysis of cell lysates derived from the prostate cancer cells used for
the colony forming assay with specific antibodies against GRP78 and b-actin.
doi:10.1371/journal.pone.0045690.g006
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the Bag-1 peptide decreases tumor cell growth in vivo in two models
of tumor xenografts (22Rv.1 and LNCaP).
The Bag-1 peptide that we found to inhibit prostate tumor cell
growth has a length of 68 amino acids, comprising helix 1 of the
BAG domain at its C-terminus and another twenty amino acids at
its N-terminus from the ubiquitin-like domain. We could
demonstrate that an N-terminal 40 amino acid fragment of this
peptide lacking the C-terminal BAG domain is still able to inhibit
growth. We could further narrow this peptide to 19 amino acids
and we identified the sequence RVMLIGK as the core for binding
to GRP78/BiP and for the inhibition of prostate tumor growth.
This sequence is very hydrophobic and agrees with earlier studies
that reported that peptides that bound the Hsp70 chaperones
including GRP78/BiP are short, at least 7 amino acids long, and
are enriched in large hydrophobic and aromatic residues [62]. The
fact that GRP78/BiP plays important roles in maintaining cellular
homeostasis and is overexpressed in different tumors [50,51,52]
makes it very likely that the peptide we have identified may not
only be important for the inhibition of prostate tumor growth but
could also be used for growth inhibition of a broad range of other
tumors. In addition, based on the evidence that cancer cells
develop drug resistance by inducing the UPR, the Bag-1 peptide
could be used to overcome this problem and to potentiate the anti-
tumorigenic effect of already existing drugs [63,64].
In addition to being an ER resident protein, recent studies have
shown that ER stress actively promotes relocalization of GRP78/
BiP on cell surface and ectopic expression also causes cell surface
relocalization in the absence of ER stress [65]. Multiple domains
of GRP78/BiP including the C-terminal substrate binding domain
shown in this work to bind the Bag-1 peptide are extracellularly
exposed [65]. Our finding that the Bag-1 peptide interacts with the
substrate-binding domain of GRP78/BiP further opens the
possibility for external application of this peptide for tumor
therapy.
Supporting Information
Figure S1 Colocalization of Bag-1 with the endoplasmic
reticulum. Immunofluorescence experiment was performed with
22Rv.1 cells fixed with 4% paraformaldehyde. After fixation, cells
were permeabilized with a solution of PBS (phosphate buffer
saline) containing 0.1% triton-X-100 and blocked with 4% goat
serum in PBS. Endogenous Bag-1 (green channel) and the
endoplasmic reticulum (red channel) were stained respectively
with a Bag-1 antibody (F-7, Santa Cruz, Heidelberg, Germany)
and the ER-tracker (Invitrogen, Karlsruhe, Germany). The
orange/yellow color indicates co-localization. Images were
aquired with a Leica TCS SPE confocal microscope (Software:
Leica Application Suite Advance Fluorescence –2.0.1 build 2043–
Leica Microsystems, Wetzlar, Germany). The bar represents
25 mm.
(TIF)
Figure S2 The Bag-1 peptide does not impair ATPase
activity of GRP78. In vitro ATPase activity assay of GRP78. A.
ATPase activity was measured with the ATPase assay kit from
Innova Bioscience (Cambridge, UK). The reaction mixture
contained GRP78 (0.5 mg) increasing amounts of GST purified
Bag-1 (continuous line) or Bag-1 peptide (dashed line) up to
1.5 mg. The reaction was carried out for 1 h at 37uC with purified
ATP according to the manufacturer’s instructions. Each point
represents the mean value of three independent experiments 6
SEM. B. The purity of protein preparation used for the assay.
Shown are 5 mg of purified GRP78 (StressMarq Biosciences,
Victoria, Canada), GST Bag-1 peptide, and GST-Bag-1 used in
the assay following SDS PAGE and Coomassie blue staining.
(TIF)
Figure S3 ATF6 expression is upregulated by thapsi-
gargin treatment. A. Real time PCR analysis of ATF6 gene
expression following thapsigargin (300 nM) treatment for the
indicated time points in 22Rv.1 cell clones with empty vector
control (open bars) and peptide-expressing clones (filled bars). The
RNA was extracted using PeqGold RNA pure (PeqLab, Germany)
kit according to manufacturer’s instructions. For gene expression
analysis, the following primers were used: Rib36 forward 59-
GAAGGCTGTGGTGCTGATGG-39; reverse 59-CCGGATAT-
GAGGCAGCAG-39; ATF6 forward 59-
TTCTTTGGCTCCCCTCCCGCA-39; reverse 59-AGTCTGG-
CAGGGTCCCACGC-39. Each bar represents the mean of three
independent experiments 6 SEM. *p,0.05. B. Western blot
analysis of ATF6 and its cleaved product (cATF6) in LNCaP cells
stably expressing the empty vector control or the Bag-1 peptide.
Anti-ATF6 specific antibody and an anti-HA specific antibody
were used for the Western blot. b-actin antibody was used to
determine equal loading control. Mouse monoclonal anti-ATF6
antibody was purchased from Imgenex (Hamburg, Germany),
mouse monoclonal anti-HA antibody (HA.11 clone 16B12) was
purchased from Covance (Munich, Germany) and anti-b-actin
antibody was purchased from Abcam (Cambridge, UK).
(TIF)
Figure S4 The Bag-1 peptide induces GCN2 phosphor-
ylation. 22Rv.1 cells stably expressing the empty vector control
or the Bag-1 peptide were treated with thapsigargin (300 nM) for
16 h and subjected to Western blot analysis using anti-phospho-
GCN2, GCN2 and HA-specific antibodies. The filters used in this
experiment for the GCN2 signals are the same filters used in
Figure 3A. The HA-Bag-1 peptide and the b-actin signals are
therefore identical to that of Figure 3A.
(TIF)
Figure S5 Knock-down of CHOP impairs the Bag-1
peptide-mediated increase in apoptosis. The action of the
Bag-1 peptide is dependent on CHOP. Pooled clones of 22Rv.1
expressing an empty expression vector (lane 1 to 4) or an HA-
tagged Bag-1 peptide (lane 5 to 8) were transfected with control
GFP siRNA (lane 1–2 and 5–6) or CHOP siRNA (lane 3–4 and 7–
8). After treatment with 300 nM thapsigargin (TG) for 24 h, cells
were lysed and Western blot was carried out with anti-PARP, anti-
CHOP and anti-HA antibodies. b-actin antibody was used to
determine the level of protein loaded on the gel.
(TIF)
Figure S6 Overexpression of the Bag-1 peptide in-
creases Capase-7 cleavage and JNK expression. 22Rv.1
cells stably transfected with an empty vector control (lane 1–2) or
a plasmid encoding an HA-tagged Bag-1 peptide (lane 3–4) were
treated with 300 nM thapsigargin (TG) for 24 h and harvested for
Western blot anaysis. Specific antibodies against JNK (Cell
Signaling, Frankfurt am Main, Germany), cleaved Caspase-7 (Cell
Signaling, Frankfurt am Main, Germany), HA (HAA.11 clone
16B12, Covance, Munich, Germany) or b-actin (Sigma, Stein-
heim, Germany) were used in the experiment.
(TIF)
Figure S7 The N-terminal Bag-1 peptide interacts with
GRP78(SBD). The N-terminal peptide binds to the SBD of
GRP78. GST-pull down assay was performed using 100 mg of cell
lysate from HEK 293 cells transfected with a plasmid expressing
an HA-tagged N-ter-Bag-1 peptide together with 10 mg of the
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indicated GST-fused protein. After the pull-down experiment,
Western blotting was performed with an anti-HA antibody to
detect the peptide. Shown is a Commassie blue staining of the
bacterially purified GST proteins to demonstrate equal loading of
the gel.
(TIFF)
Text S1 Homology-basded structure prediction of the
Bag-1 peptide.
(DOCX)
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